Senseonics Holdings Inc (NYSEAMERICAN:SENS) – Svb Leerink lowered their Q1 2019 earnings per share estimates for shares of Senseonics in a research report issued on Tuesday, March 12th. Svb Leerink analyst D. Antalffy now forecasts that the company will earn ($0.06) per share for the quarter, down from their prior estimate of ($0.05). Svb Leerink also issued estimates for Senseonics’ Q3 2019 earnings at ($0.07) EPS, FY2019 earnings at ($0.25) EPS, Q1 2020 earnings at ($0.05) EPS, Q3 2020 earnings at ($0.07) EPS, Q4 2020 earnings at ($0.07) EPS, FY2020 earnings at ($0.24) EPS and FY2021 earnings at ($0.20) EPS.
Senseonics (NYSEAMERICAN:SENS) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.11. The business had revenue of $7.20 million for the quarter, compared to analyst estimates of $7.89 million.
SENS stock opened at $2.58 on Friday. Senseonics has a 1 year low of $2.15 and a 1 year high of $5.29.
Several institutional investors have recently bought and sold shares of SENS. Amalgamated Bank bought a new position in shares of Senseonics during the 4th quarter worth approximately $28,000. First Allied Advisory Services Inc. bought a new position in shares of Senseonics during the 4th quarter worth approximately $35,000. Great West Life Assurance Co. Can purchased a new stake in shares of Senseonics during the 4th quarter worth approximately $41,000. Frontier Investment Mgmt Co. purchased a new stake in shares of Senseonics during the 4th quarter worth approximately $52,000. Finally, Cerity Partners LLC increased its stake in shares of Senseonics by 33.3% during the 4th quarter. Cerity Partners LLC now owns 20,000 shares of the company’s stock worth $52,000 after purchasing an additional 5,000 shares during the last quarter. 30.66% of the stock is currently owned by hedge funds and other institutional investors.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Further Reading: The risks of owning bonds
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.